Cognitive dysfunction in Moyamoya disease: latest developments and future directions

Xilong Wang1, Ziqi Liu1, Zhenyu Zhou1

  • 1Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.

PubMed

Insights

Moyamoya disease (MMD) commonly causes cognitive dysfunction, affecting memory and executive functions. More research is needed to understand MMD

Area of Science:

  • Neuroscience
  • Neurology
  • Medical Research

Background:

  • Cognitive dysfunction is a frequent complication of Moyamoya disease (MMD).
  • Existing knowledge regarding cognitive impairment in MMD is insufficient.
  • MMD affects various cognitive domains, including executive function, intelligence, and memory.

Purpose of the Study:

  • To review the characteristics of cognitive function alterations in MMD.
  • To provide recommendations for future research on MMD-related cognitive dysfunction.

Main Methods:

  • Literature review of studies on cognitive function in Moyamoya disease.
  • Analysis of cognitive deficits reported in MMD patients.
  • Synthesis of current understanding and identification of research gaps.

Main Results:

  • MMD is associated with characteristic declines in executive function, intelligence, and memory.
  • The impact of cerebral revascularization surgery on cognitive impairment in MMD remains controversial.
  • There is a significant lack of comprehensive research on cognitive impairment in MMD.

Conclusions:

  • Cognitive dysfunction is a key feature of Moyamoya disease, necessitating further investigation.
  • Future research should focus on the pathogenesis, etiology, and long-term cohort studies of MMD.
  • Understanding and addressing cognitive impairment in MMD is crucial for patient care and management.

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
444
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
95
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
94